The GABA B receptor was the first G protein-coupled receptor identified as an obligate heterodimer. It is composed of two subunits, GABA B1 containing the agonist binding site and GABA B2 responsible for G protein activation. The GABA B receptor was found to associate into larger complexes through GABA B1 -GABA B1 interactions, both in transfected cells and in brain membranes. Here we assessed the possible allosteric interactions between GABA B heterodimers by analyzing the effect of mutations located at the putative interface between the extracellular binding domains. These mutations decrease, but do not suppress, the F€ orster resonance energy transfer (FRET) signal measured between GABA B1 subunits. Further analysis of one of these mutations revealed an increase in G protein-coupling efficacy and in the maximal antagonist binding by approximately two-fold. Hypothesizing that a tetramer is an elementary unit within oligomers, additional FRET data using fluorescent ligands and tagged subunits suggest that adjacent binding sites within the GABA B oligomers are not simultaneously occupied. Our data show a strong negative effect between GABA B1 binding sites within GABA B oligomers. Accordingly, GABA B receptor assembly appears to limit receptor signaling to G proteins, a property that may offer novel regulatory mechanism for this important neuronal receptor.
Introduction
g-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the adult central nervous system, limits neuronal excitability predominantly by inducing membrane hyperpolarization and reducing neurotransmitter release. The GABA B receptor is a G protein-coupled receptor (GPCR), broadly expressed in the brain and key player in GABAergic inhibition. It is known to inhibit Cav2 channels that controls neurotransmitter release at both excitatory and inhibitory presynaptic terminals; and to activate postsynaptic Kir3 channels in dendrites, promoting post-synaptic membrane hyperpolarization (Bettler et al., 2004; Ulrich and Bettler, 2007) . Accordingly, the GABA B receptor plays a pivotal role in the modulation of many pathways throughout the brain (Bowery et al., 2002) .
Preclinical studies using both, GABA B receptor agonists and antagonists, suggested that the GABA B receptor could be an attractive target for the development of therapeutics for many neurological disorders including alcoholism, addiction, anxiety or depression (Cryan and Kaupmann, 2005; Filip et al., 2015) . However, only two agonist molecules are currently in the clinic: baclofen (Lioresal ® ), which is a muscle relaxant indicated for multiple sclerosis and currently under investigation for alcoholism treatment; and GHB (Xyrem ® ), a molecule to treat narcolepsy. The spectrum of therapeutic indications of these compounds is rather limited due to the associated side effects. To overcome this limitation, we would benefit from a more accurate knowledge of the mechanism of action of GABA B ligands. The GABA B receptor belongs to the class C of the GPCR family together with the metabotropic glutamate receptors or the calcium sensing-receptor among others . It is characterized by a large and structured extracellular domain called Venus Flytrap (VFT) and linked to a seven transmembrane core (7TM) (Fig. 1A) . The GABA B receptor is an obligatory heterodimer, composed of the GABA B1 and GABA B2 subunits. GABA B1 binds GABA in its VFT and GABA B2 plays a major role in G protein activation (Galvez et al., 2001; Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998) . The heterodimers are stabilized by a coiled-coil interaction involving the intracellular C-termini as well as additional non-covalent interactions between their VFTs and 7TMs (Burmakina et al., 2014; Geng et al., 2013; Kammerer et al., 1999; Kuner et al., 1999) . The coiled-coil interaction directly participates in a quality control of heterodimerization since GABA B1 is retained in the endoplasmic reticulum (ER) unless the ER retention signal present in its C-terminus is masked through the coiled-coil interaction with GABA B2 allowing the heterodimer to reach the plasma membrane (Calver et al., 2001; Margeta-Mitrovic et al., 2000; Pagano et al., 2001 ).
More recently, we and others reported that the GABA B receptor was associating into larger oligomeric entities (Calebiro et al., 2013; Comps-Agrar et al., 2011; Maurel et al., 2008) . Indeed, when GABA B heterodimers were expressed at the cell surface, a significant lanthanide resonance energy transfer (LRET) was measured between two GABA B1 subunits, indicating a direct interaction between GABA B1 subunits from distinct heterodimers (Comps-Agrar et al., 2011; Maurel et al., 2008) . This LRET was quantified using time-resolved F€ orster resonance energy transfer (TR-FRET) measurement in which a delay is observed between light excitation and emission recording. In addition, by using single molecule microscopy, Calebiro and colleagues showed that even at low density, a large proportion of GABA B receptor tetramers could be detected. They also observed even larger entities when the receptor density increased (Calebiro et al., 2013) . Furthermore, mass spectrometry analysis and TR-FRET measurements also support the existence of GABA B receptor oligomer in the brain (Comps-Agrar et al., 2011; Schwenk et al., 2010) . These findings give rise to important Fig. 1 . GABA B receptor oligomerization and destabilization by N380 þ T382 mutation. A. Schematic representation of the GABA B receptor subunits, the SNAP-Tag (ST) and the N380 þ T382 (NT) mutation. B. GABA B receptors structure where the mutated residues positions are highlighted by colored spheres: 380 and 382 (orange); 410 and 412 (green) and 413 (purple) (GABA B1a numbering). GABA B1 subunit is represented in grey, GABA B2 subunit in black. The image was generated using pymol. The pdb code for the GABA B VFT dimer structure is 4MQE. C. Measurement of TR-FRET signal between GABA B receptor subunits over a large range of cell surface expression. HEK293 cells were transfected with ST-GABA B1 and GABA B2 (black), ST-GABA B1 -NT and GABA B2 (orange) or GABA B1 and ST-GABA B2 (blue) and labeled either with an optimized amount of the SNAP-Lumi4Tb (donor) and SNAP-Red (acceptor) for TR-FRET signal recording or with a saturating concentration of SNAP-Lumi4Tb for determination of cell surface expression. Both the TR-FRET signal and cell surface expression were determined and plotted (data points from 4 independent experiments each performed in three replicates). D. Co-immunoprecipitation of GABA B receptor oligomers. HEK293 cells were transfected with cDNA encoding the indicated proteins. After immunoprecipitation using an anti-Flag antibody, HA-tagged proteins were detected by western blot using an anti-HA antibody. Total expression of HA-tagged protein was also assessed. (Gels are representative of 4 independent experiments).
questions regarding the molecular and pharmacological transitions within the oligomers and its implication in pathology. In a previous study, the functional characterization of various oligomeric entities led us to propose a regulation of the G protein-coupling efficiency mediated by the GABA B receptor oligomerization. By using an engineered GABA B1 -like competitor (a GABA B1 subunit deleted of its C-terminus and in which the GABA binding site is mutated) or by introducing mutations in GABA B1 VFT (E380N þ L382T), we measured a decrease in the oligomer TR-FRET signal, which was correlated with an increased efficacy in G protein-coupling as measured using the chimeric Gqi9 G protein that forces Gi-coupled receptors to activate the phospholipase C (PLC) pathway (CompsAgrar et al., 2011) . These data suggest that the G protein signaling is restrained by the oligomerization of the GABA B receptor heterodimers through an unknown molecular mechanism.
In the present study, we aimed at better understanding the properties of the GABA B receptor oligomers by conducting further characterization of a GABA B1 VFT mutant. We show that mutations at the VFT interface alter the oligomeric organization but do not fully prevent the formation of oligomers since oligomers can still be detected. Using one of the mutants, we demonstrate that mutating the VFT interface largely increases coupling efficacy to natural signaling of the GABA B receptor independently of any change in the agonist or antagonist affinity. This mutant also results in an approximately 2-fold increase in the number of binding sites. With additional LRET analysis of ligand interaction, our data support a strong negative effect between binding sites within the oligomer such that not all GABA B1 VFT in the oligomers simultaneously bind a ligand. We propose that the GABA B1 VFT interaction within the oligomers promotes allosteric interactions between the VFTs that likely limit the number of active heterodimers in the oligomer to one per tetrameric unit.
Materials and methods

Chemicals
Unless stated otherwise, compounds were purchased from Sigma Aldrich (St Quentin Fallavier, France).
Plasmids
cDNAs encoding the GABA B subunits or mGlu2 with various tags (HA, cMyc, Flag or ST) and mutations were cloned in pRK5 plasmid and described previously (Doumazane et al., 2011; Maurel et al., 2008) . Plasmid encoding cAMP EPAC sensor was obtained from Dr Lily Jiang (University of Texas Southwestern, Dallas).
Cell culture and transfection
Human embryonic kidney (HEK293) cells (ATCC ® CRL-1573™, Molsheim, France) were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Life Technology, Cergy Pontoise, France) supplemented with 10% fetal bovine serum (Sigma Aldrich) at 37 C under 5% CO 2 . The cells were regularly tested and were mycoplasmfree (MycoAlert, Lonza, Levallois, France). Cells were transiently transfected either by electroporation as previously described or using lipofectamine 2000 (Life Technology) using the manufacturer instructions. Following transfection, cells were seeded out either in 96-well microplates or 10 cm dishes and cultured for 24 h.
TR-FRET determination between ST-fused receptors
Cell surface receptors fused to a Snap-Tag (ST) were labeled using the non-cell-permeant fluorescent substrates: SNAPLumi4Tb and SNAP-Red in Tag-Lite buffer (Cisbio bioassays, Codolet, France) at 37 C for 1 h. For TR-FRET measurement, the optimal concentrations were 100 nM of SNAP-Lumi4Tb and 600 nM of SNAP-Red. After 3 washes in Krebs buffer (10 mM Hepes pH 7.4, 146 mM NaCl, 4.2 mM KCl, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 5.6 mM glucose, bovine serum albumin 0.1%), fluorescence was measured in a RUBYstar plate reader (BMG Labtech, Champigny sur Marne, France) using the following excitation e detection parameters: laser excitation 337 nme20 flashes; donor detection: 620 nm; acceptor detection: 665 nm. TR-FRET parameters delay: 50 ms; integration time: 400 ms. TR-FRET is calculated as the TR-FRET intensity, where the non-specific LRET due to random collisions and the contamination of the donor at the TR-FRET wavelength (665 nm) are subtracted. TR-FRET intensity ¼ (signal at 665 nm measured on cells co-labeled with the donor and the acceptor) e (signal recorded on the same transfection labeled with the donor in absence of acceptor).
Cell surface expression determination by ST labeling
Cells from the same transfection as for the TR-FRET measurement were labeled at a saturating concentration of 300 nM SNAPLumi4Tb in Tag-Lite buffer at 37 C for 1 h. After 3 washes in Krebs buffer, fluorescence was measured in a RUBYstar plate reader using the same parameters as for the TR-FRET measurement. Cell surface expression levels were calculated as the difference between the signal recorded at 620 nm on cells expressing the receptor and the signal recorded at 620 nm on mock transfected cells incubated with SNAP-Lumi4Tb.
Co-immunoprecipitation
Cells were transfected by electroporation (described above) with a 50:50 mix of HA-GABA B1 and Flag-GABA B1 co-expressed with cMyc-GABA B2 , and seeded into 100 mm cell culture dishes. 24 h post-transfection cells were washed in ice-cold PBS then harvested in ice-cold lysis buffer (HEPES, 5 mM; NaCl 300 mM; 20% v/v; glycerol, 9% v/v; dodecyl maltoside, 0 .4% w/v, Roche protease inhibitor cocktail, 1 tablet); lysates were centrifuged to remove the nuclear fraction and a sample was assayed for protein content (BCA reaction, ThermoFisher). Samples were separated for input (5 mg) and immunoprecipitation (IP) (10 mg). Samples for IP were pre-cleared with Protein G agarose beads and then probed under gentle agitation for 16 h at 4 C with anti-Flag antibodyconjugated agarose beads, the samples for input were kept under the same conditions in the absence of agarose beads. After incubation the IP samples were centrifuged at low speed and washed three times in ice-cold lysis buffer. After the third wash the beads were resuspended into 4x SDS sample buffer (200 mM Tris-Cl (pH 6.8), 8% SDS (sodium dodecyl sulfate), 0.4% Bromophenol blue, 40% glycerol), as were the input samples. Samples were run on NuPage 3e8% Tris acetate gels (ThermoFisher) and subsequently transferred to PVDF membranes, blocked and probed with primary antibody (rabbit anti-HA or mouse anti-Flag, 1:1000) 16 h at 4 C; after washing, membranes were probed with secondary antibody (anti-mouse-or anti-rabbit-HRP) 60 min at room temperature, washed, then detected using Pierce SuperSignal Pico kit (ThermoFisher) and Amersham Hyperfilm (GE Life sciences).
Determination of cAMP production by bioluminescence resonance energy transfer (BRET)
Cells were transfected with the indicated receptor subunits and with BRET Epac (cAMP) sensor, Camyel (Jiang et al., 2007) . 24 h post-transfection cells were washed in Assay buffer (150 mM NaCl, 2.6 mM KCl, 1.2 mM MgCl2, 10 mM dextrose, 10 mM HEPES, 2.2 mM CaCl2, 0.5%(w/v) bovine serum albumin, pH 7.4) and replaced with fresh assay buffer. Coelentrazine H (ThermoFisher) was added to each well for 5 min, 10 mM forskolin for 5 min and GABA for 10 min.
The BRET signal was recorded at that time point (10 min after GABA addition) using a Mithras LB940 plate reader (Berthold, Thoiry, France) at 485 nm (Renilla Luciferase) and 530 nm (YFP). The BRET signal was expressed as the ratio of the signal at 530 nM divided by the signal at 485 nM and normalized to the wild-type response (no GABA ¼ 0%; 1 mM GABA ¼ 100%).
CGP54626-red fluorescence binding experiments
For saturation binding experiments, cells transfected with the indicated receptor subunits were placed at 4 C and washed twice with ice-cold Tris Krebs buffer (20 mM Tris, 118 mM NaCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 4.7 mM KCl, 1.8 mM CaCl 2 , pH 7.4). The cells were then incubated with increasing concentrations of the fluorescently labeled antagonist, DY647-CGP54626 (CGP54626-Red; 0e30 nM) for 3 h at 4 C. Non-specific binding was determined for each concentration in the presence of 1 mM GABA. The cells were then washed three times quickly with ice-cold Tris Krebs buffer to remove the unbound ligand.
Competition binding experiments were performed using increasing concentrations of GABA or CGP54626 in the presence of K D concentration of CGP54626-Red (Cisbio), 10 mM non-labeled CGP54626 (Tocris) was used to determine non-specific binding.
The fluorescence was immediately measured using an Infinite F500 plate reader (Tecan, Lyon, France) using a xenon lamp excitation at 610 nm (10 flashes) and a detection wavelength at 670 nm over 1 ms. The signal was expressed as the difference of fluorescence signal at 670 nm between CGP54626-Red and CGP54626-Red in the presence of GABA.
Cell surface ELISA
Cell surface ELISA has been performed us previously described (Maurel et al., 2008) using HA-tagged GABA B1 subunits (wild-type or mutant) and the HRP-conjugated anti-HA clone 3F10 from Roche (Sigma).
TR-FRET and fluorescence measurements using fluorescent antagonists
Cells transfected with the GABA B subunits were washed twice with ice-cold Tris Krebs buffer and then incubated at 4 C for 3 h with 10 nM CGP54626-Lumi4Tb and increasing concentrations of CGP54626-Red. After 3 quick washes with ice-cold Tris Krebs buffer to remove unbound ligands, TR-FRET and fluorescence signal were recorded immediately using both a RUBYstar (TR-FRET, 620 nm) and an Infinite F500 (670 nm) plate readers using the parameters indicated in the previous sections. Unspecific binding was assessed using 1 mM GABA and subtracted from the signal.
Data analysis
Data were analyzed using the GraphPad software (San Diego, CA, USA).
2.11.1. For saturation fluorescence binding data, non-specific and total binding data were fitted according to the following equation 2.11.3. Concentration-response data generated from cAMP inhibition assays were fitted according to the following threeparameter logistic equation
where E is effect, E max and basal are the top and bottom asymptotes of the curve, respectively, [A] is the agonist concentration, and pEC 50 is the negative logarithm of the agonist concentration that gives a response halfway between E max and basal.
Results
Alteration of GABA B oligomeric organization by mutating GABA B1 VFT
Based on the analysis of the VFT-containing tetrameric AMPA receptor GluR2 crystal structure (Sobolevsky et al., 2009 ), we previously proposed a patch of residues within GABA B1 VFT likely involved in the GABA B receptor oligomerization interface (CompsAgrar et al., 2011) . We confirmed these observations here using previously reported and novel mutants, all located in the same region in the GABA B1 VFT (E380N þ L382T; T410N þ E412T; E413N) (Fig. 1B) . We used N-terminal SNAP-tagged (ST) version of GABA B1 that can be labeled specifically at the cell surface using non cellpermeant SNAP substrates, SNAP-Lumi4Tb or SNAP-Red, compatible with LRET (Fig. 1A) . HEK293 cells were transfected with GABA B2 and with increasing concentrations of GABA B1 wild-type or mutant. After labeling with an optimized ratio of SNAP-Lumi4Tb and SNAPRed, the TR-FRET signal was recorded. In parallel, the cell surface expression of GABA B heterodimers was determined by labeling ST at a saturating concentration of SNAP-Lumi4Tb. Although all the mutations decreased the TR-FRET signal measured between GABA B1 subunits at any cell surface expression, none of them suppressed the TR-FRET signal (Fig. 1C) . Compared to the low TR-FRET signal recorded between ST-GABA B2 subunits that do not directly interact, the signal recorded when using the mutated ST-GABA B1 subunits was higher (Fig. 1C) . The decrease in TR-FRET signal recorded using the NT mutant compared to the wild type receptor suggest that at least some heterodimers as still in close proximity, since the signal is not entirely ablated. This could be either because of conformational changes in oligomers that alters the interaction at the VFT level and increasing the distance between GABA B1 -VFT or because of the dissociation of some oligomers into isolated heterodimers.
To better understand the nature of the residual interaction of the abovementioned mutants observed in the TR-FRET studies, coimmunoprecipitation experiments were performed with one of the GABA B1 mutants carrying both the E380N and L382T mutations (herein referred to as GABA B1 -NT). In HEK293 cells we co-expressed both HA-and Flag-tagged GABA B1 wild-type or HA-and Flagtagged GABA B1 -NT together with GABA B2 and performed an antiFlag immunoprecipitation followed by an anti-HA immunoblot (Fig. 1D ). The data demonstrate that the heterodimers containing GABA B1 -NT could still be co-immunoprecipitated, but maybe to a lesser extent than the wild-type heterodimers (Fig. 1D) . This supports the idea that the oligomeric assembly is not completely disrupted when introducing the mutation, and that perhaps an interaction in the 7TM regions could still exist, as observed under specific conditions for mGlu 2 receptor (Xue et al., 2015) . As a negative control, we used HA-mGlu2 homodimers that could not be immunoprecipitated by Flag-GABA B heterodimer, which also suggests that the GABA B1 -NT band is unlikely due to non-specific binding to the agarose beads. Taken together, these coimmunoprecipitation experiments suggest that the GABA B1 -NT mutation is not sufficient to completely prevent the oligomeric interaction between GABA B heterodimers. Altogether, our data indicate that the NT mutation in GABA B1 very likely disturbs the GABA B1 VFTs interaction within the oligomer, thus weakening the interaction between the GABA B receptors.
GABA B receptor oligomerization reduces native Gi proteincoupling efficiency
We then characterized further the pharmacological consequences of the oligomer destabilization induced by the NT mutant in GABA B1 . We first assessed the effect of the mutation on G protein activation. The GABA B receptor is endogenously coupled to the Gi/o protein family, which inhibits adenylyl cyclase activity, hence decreasing elevated cAMP levels (Bowery et al., 2002) . Here, we used the cAMP CAMYEL sensor to directly monitor cAMP level in transfected cells (Fig. 2A) . CAMYEL is a BRET sensor that changes conformation upon cAMP binding; in the absence of cAMP, the BRET signal is high and in the presence of cAMP, the signal decreases (Jiang et al., 2007) . HEK293 cells were transfected with CAMYEL and with either the wild-type or the NT mutant receptor. cAMP production was induced by forskolin addition before stimulating the receptor with increasing concentrations of GABA. As expected, the BRET signal increased in the presence of GABA since it reduced cAMP level (Fig. 2B) . When comparing the signals obtained using the wild-type GABA B1 or GABA B1 -NT, the GABA potency was similar for both conditions (wild-type: pEC50 ¼ 5.80 ± 0.12; NT: pEC50 ¼ 5.91 ± 0.39), while the maximal response was higher for GABA B1 -NT (182 ± 24% of wild-type response) despite a similar cell surface expression (107 ± 13% of wild-type expression as determined by ELISA). This suggests that the efficacy of G protein response is tightly regulated by the oligomer conformation of the GABA B receptor. This observation is in line with our previous study using the Gqi9 chimeric G protein that allows Gi coupled receptors to signal via the PLC/IP/Ca 2þ axis (Comps-Agrar et al., 2011) . Taken together, these observations support the idea that the GABA B1 -NT alters the properties of the GABA B receptor oligomers; therefore providing insight into the link between oligomeric conformation and state and agonist efficacy.
GABA B receptor oligomerization alters the orthosteric ligand binding properties
We hypothesized that the limitation of the coupling efficacy in oligomers was related to negative allosteric transitions between heterodimers within the oligomers. To verify this, we analyzed the ligand binding properties of the wild-type and NT oligomers as allosteric transitions within GPCR oligomers may be reflected upon the apparent binding affinity. We first performed a competitive binding assay to compare the affinity of GABA, the endogenous agonist, and of CGP54626, an orthosteric inverse agonist, for the intact versus the destabilized GABA B oligomers. We transfected cells with the vectors encoding the wild-type or the NT mutant GABA B receptors and carried out cell surface competition binding experiments using the non-permeant fluorescent antagonist (CGP54626-Red) as a tracer (Fig. 3A) . When displacing the tracer with the unlabeled CGP54626, the IC 50 was similar for both receptor constructs (wild-type: pIC 50 ¼ 8.88 ± 0.14; NT: pIC 50 ¼ 8.90 ± 0.21). Similarly, GABA IC 50 value was not altered when introducing the mutation that destabilized the oligomer (wild-type: pIC 50 ¼ 5.12 ± 0.10; NT: pIC 50 ¼ 5.09 ± 0.12). These data indicate that the apparent affinity of the ligands was not modified when destabilizing the oligomers.
Using the fluorescent antagonist, we also performed saturation binding experiments on cells expressing either the wild-type or the NT GABA B receptor to better characterize the binding properties of the different oligomeric states, specifically apparent B max . We ensured that we had a similar cell surface expression of the Fig. 2 . Measurement of intracellular cAMP level upon GABA B receptor activation using a BRET-based EPAC sensor. Increasing concentrations of GABA were applied to HEK293 cells expressing either GABA B1 and GABA B2 (black) or GABA B1 -NT and GABA B2 (orange) and CAMYEL cAMP sensor and the resulting BRET signal was recorded. The signal is expressed as a percentage of the wild-type receptor response and each data point is the average of three independent experiments ± S.E.M., where each experiment was performed in duplicate. receptor between the two conditions (wild-type: 2.16 Â 10 6 ± 0.07 Â 10 6 RLU; NT: 2.41 Â 10 6 ± 0.07 Â 10 6 RLU in cell surface ELISA (Fig. 3B) (Fig. 3C ). This indicated that, despite equivalent surface expression per se, the apparent number of CGP54626-Red binding sites at the equilibrium was increased. This suggests that whilst the number of binding sites is theoretically equivalent across both wild-type and NT receptor, only about half of these sites are accessible at the wild-type. Altogether, these observations suggest a strong negative effect between orthosteric binding sites within the oligomers preventing the simultaneous occupancy of all orthosteric sites. This may be the consequence of an allosteric control between VFTs and the result of a steric hindrance making some of the sites non-accessible to the ligand, which also constitutes a form of allostery.
No LRET is detected between adjacent binding sites within the GABA B oligomer
We decided to address the proposed negative effect between binding sites by taking advantage of CGP54626 derivatized with the LRET compatible fluorophores Lumi4Tb and Red. Previously, we have shown that GABA B1 subunits were in close proximity within the oligomers as evidenced by the high TR-FRET signal measured between ST fused GABA B1 VFTs (Fig. 1A) . We could thus reasonably hypothesize that the simultaneous binding of CGP54626-Lumi4Tb and CGP54626-Red to orthosteric binding sites, located within GABA B1 VFTs would give rise to a significant TR-FRET signal. HEK293 cells were transiently transfected with vectors encoding GABA B receptor and incubated with 10 nM CGP54626-Lumi4Tb (twice the Kd of the fluorescent antagonist) and increasing concentrations of CGP54626-Red. After washes, the amounts of CGP54626-Lumi4Tb and CGP54626-Red bound to the cells were quantified by direct measurement of the fluorescence of each fluorophore at their respective wavelength, and subsequently the TR-FRET signal was also measured. We observed that with increasing concentrations of CGP54626-Red, the less Lumi4Tb was bound to the cells, which is in line with a competition between the two fluorescent antagonists (Fig. 4A) . Moreover, the two curves cross at 50% of maximal binding indicating a site-occupancy with 50% LRET donor antagonists and 50% LRET acceptor antagonists, which are optimal conditions for LRET to occur. Surprisingly, we did not observe the expected TR-FRET bell-shape curve, with the maximal signal obtained for an equi-binding of the two fluorescent antagonists, as previously shown for TR-FRET between SNAP tags (Maurel et al., 2008) , or between oxytocin receptor antagonists (Albizu et al., 2010) . Instead, we obtained a sigmoidal curve that resembled that of Lumi4Tb fluorescence (Fig. 4B) . In addition, the signal recorded was very weak, which rather suggests a bleedthrough of Lumi4Tb emission into the TR-FRET channel and supports an absence of actual LRET between fluorescently derivatized antagonists within the GABA B oligomers.
To determine the impact of the derivatization of CGP54626 with the fluorophores on the photo-physical properties of the chromophores, we tested whether a TR-FRET signal could be recorded between a ST fused at the N-terminus of GABA B1 or GABA B2 and the fluorescent CGP54626 bound to GABA B1 . We obtained a significant TR-FRET signal on cells transfected with ST-GABA B1 and GABA B2 and labeled with CGP54626-Lumi4Tb and SNAP-Red and conversely with CGP54626-Red and SNAP-Lumi4Tb (data not shown), confirming that the fluorescent antagonists are suitable for LRET studies even after binding to GABA B1 VFT. In addition, we verified that the CGP54626 moiety was still able to bind to GABA B1 with a high affinity (4.98 and 4.91 nM for CGP54626-Lumi4Tb and CGP54626-Red, respectively).
We then directly compared the different TR-FRET signals that could be measured within the GABA B oligomer using ST and fluorescent antagonist labeling. Indeed, by transfecting HEK293 cells with vectors encoding ST-GABA B receptor, we could study three different LRET combinations: the LRET between two SNAP tags; the LRET between an ST and an antagonist; and the LRET between two antagonists. Cells from the same transfection could be labeled with each combination of fluorescent ligands and substrates and therefore all the resulting TR-FRET measurements could be directly compared (Fig. 4C) . When the ST was fused to GABA B2 , the TR-FRET signal between ST was low as previously shown (Fig. 1) . A high TR-FRET signal was measured between CGP54626-Lumi4Tb and SNAPRed and this signal was even higher when ST was fused to the GABA B1 subunit. This is congruent with a shorter distance between Increasing concentrations of GABA (circle) or unlabeled CGP54626 (triangle) were applied to HEK293 cells expressing GABA B1 and GABA B2 (black) or GABA B1 -NT and GABA B2 (orange) in the presence of 10 nM of Red-CGP54626. The signal is expressed as a percentage of initial binding and each data point is the average of three independent experiments ± S.D., each performed in triplicate. B. Saturation binding of GCP54626-Red. Increasing concentrations of CGP54626-Red were applied to HEK293 cells expressing GABA B1 and GABA B2 (black) or GABA B1 -NT and GABA B2 (orange). Inset: GABA B cell surface expression measured by ELISA against N-terminal HA-tagged GABA B1 . Each data point is the average of three independent experiments ± S.D., each performed in triplicate.
the antagonist, bound to GABA B1 VFT, and the ST fused to GABA B1 rather than fused to GABA B2 . When using a combination of CGP54626-Lumi4Tb and CGP54626-Red, no significant TR-FRET signal could be detected independently of the ST fusion used. This result suggests that two consecutive binding sites are unlikely to be occupied at the same time within the oligomer and further supports the existence of a negative effect between adjacent GABA B1 binding sites. Of note, when using GABA B1 -NT and GABA B2 , we could not detect any TR-FRET signal between antagonists either ( Supplementary Fig. 1 ). Such finding may appear surprising when considering the increase in apparent number of binding sites thus the number of bound antagonists at the equilibrium. However, it is possible that the destabilization of the VFT association resulting from the N380 þ T382 mutation increases the mean distance between two GABA B1 binding sites such that these are too distant for an efficient LRET to occur.
Discussion
The discovery that the GABA B receptor was an obligatory heterodimer was a breakthrough in the GPCR field, highlighting the possibility that other GPCRs may also associate in heterodimeric entities. More recently, GABA B receptor heterodimers were shown to associate into larger entities, both in transfected cells and in the brain (Calebiro et al., 2013; Comps-Agrar et al., 2011; Maurel et al., 2008; Schwenk et al., 2010) , raising questions regarding the significance, the properties and the structural organization of such complexes. Here we have characterized a mutant that destabilizes the oligomer interface at the level of the VFT. This is well illustrated by a decrease in the TR-FRET signal between GABA B1 VFTs. In this mutant the allosteric interactions between the GABA B receptors within the oligomers are prevented as shown by the increase of both the G protein-signaling efficacy and the number of binding sites. Further LRET studies between ligands, and between the ligand and the subunits are consistent with a decrease of occupied binding sites in the oligomer down to a single ligand bound per GABA B tetrameric unit, despite the presence of two identical binding sites. Taken together our data revealed a strong negative effect between the GABA B1 VFTs within the oligomer. Because some binding sites seem to be inaccessible at the concentration range of the ligand used, one cannot exclude that this negative effect results from a steric hindrance of the binding sites by the other VFTs (ie a form of allostery), although this is difficult to explain considering the structure of the VFT.
Although a direct interaction between the GABA B1 subunits of the heterodimer is essential for the formation of larger GABA B complexes, the precise molecular organization of the oligomer is still unknown. We have previously reported that the GABA B1 VFT plays a critical role in the formation of the oligomers (Comps-Agrar et al., 2011) . At the tetrameric ionotropic glutamate receptors (iGluRs), the amino-terminal extracellular domain of each subunit is a VFT similar to those of GABA B subunits. Several high-resolution structures of iGluRs were solved and revealed two main possibilities for two VFT dimers to interact (Herguedas et al., 2016; Lee et al., 2014; Sobolevsky et al., 2009; Zhu et al., 2016) . A first arrangement involves a small area of the C-terminal lobes of the VFTs, while a second and more compact arrangement involves a larger interface. Cryo-electron microscopy analyses confirm that both arrangements could be detected for the same iGluR and may correspond to different states of the channel (Herguedas et al., 2016) . We hypothesized that the oligomeric GABA B interaction at the VFT level may mimic the less compact form of iGluR VFTs with GABA B1 VFTs constituting the central core and GABA B2 VFTs being further apart. Accordingly, we mutated residues in the loop that may be part of the interface and that is poorly conserved in VFT proteins. We showed here that mutating GABA B1 in this region significantly altered GABA B1 -GABA B1 interaction at low as well as at high expression levels, as evidenced by the lower TR-FRET signal between the N-terminal SNAP tags. Since the ligand affinity was not altered by the mutations, it is unlikely that the folding of the VFT is modified but rather that the general organization of the oligomer is altered. Of note, the fluorophore pair that is used in this study is not sensitive to the dipole orientation such that the TR-FRET signal is dependent mainly on the distance between the fluorophores, and also on the proportion of fluorophores involved in FRET. Two hypotheses can be raised to explain this LRET observations: either the mutations largely prevent the formation of the oligomers such that most of the receptors expressed at the cell surface are strict heterodimers and the TR-FRET signal recorded is due to a small proportion of GABA B oligomers still present at the cell surface; or the mutations change the conformation of the oligomers such that the GABA B1 -VFT are more distant than in the wild-type but most of the receptors are still oligomeric. Our observation that the mutations decrease the TR-FRET signal measured between GABA B1 VFTs to values that are still higher than the negative control, and that GABA B1 co-immunoprecipitation can still be detected, though maybe to lesser extent, is compatible with either hypotheses or with the combination of the two. Altogether, our data bring strong evidence for i) the poorly conserved loop encompassing the residues Glu380 and Leu382 directly participating in the VFT oligomerization interface and ii) the existence of other molecular determinants in the oligomeric interface, possibly in the 7TMs as observed under certain conditions between mGlu 2 receptor dimers (Xue et al., 2015) . To gain better knowledge of the molecular organization of the GABA B receptor oligomers, more work is needed, and clearly the determination of the structure of the full-length receptor or at least VFT tetramer would be important.
No matter the exact mode of association of the GABA B1 subunits, it is clear that the N380 þ T382 mutation affects the allosteric interaction between the GABA B receptor heterodimers in the oligomer. We previously reported that expression of competing inactive GABA B1 subunits that prevents the formation of GABA B oligomers almost doubles the receptor-coupling efficacy to a PLC activating G protein chimera (Comps-Agrar et al., 2011) . Although such an effect could be the consequence of allosteric interaction between the competitor and the functional heterodimer, our observation that mutations at a possible GABA B1 VFT dimer interface had the same effect, is in favor of a negative functional cooperativity between the GABA B heterodimers. In the present study we confirm that it is indeed the case even when examining the coupling of the N380 þ T382 mutant to its natural pathway involving Gi proteins with approximately twice the maximal response of wild-type oligomers. Such a finding suggests that an allosteric interaction between the GABA B1 VFTs within the oligomer is essential to control Gi protein coupling efficacy, and that the NT mutation suppresses this inhibitory allosteric interaction even without fully preventing oligomer formation.
The existence of an allosteric interaction between VTFs is further clearly demonstrated when analyzing the binding properties of the fluorescent ligand CGP54626-Red, revealing that the apparent number of binding sites is almost double when using GABA B1 -NT compared to the wild-type subunit, without any significant change in affinity. This indicates that in average, for an equivalent number of GABA B heterodimers, fewer CGP54626 molecules bind to the oligomer; and that destabilizing their molecular organization results in an increase in the number of bound antagonists. In other words, this strongly suggests that the mutation removes a steric hindrance or disrupts some subtle molecular switches that prevent the simultaneous occupancy of all the binding sites by the orthosteric antagonist and then reveals a strong negative allostery within the oligomer. This is supported by the lack of LRET between CGP54626 labeled with a donor and an acceptor. Moreover, because LRET can be measured between GABA B1 VFT N-termini, and because the orthosteric binding site is in the GABA B1 VFT (Galvez et al., 2000) , the distance between binding sites is likely to be compatible with LRET. Altogether, this supports a strong negative effect for antagonist binding within the oligomers such that, at the equilibrium, only a fraction of the sites can be occupied.
Does the negative effect also apply to agonists? So far, we do not have access to a fluorescent or a radioactive agonist with a high enough affinity to reproduce the experiments performed with the antagonist. However, we may hypothesize that the negative effect is also likely to occur for agonists. Indeed, the reduced efficacy in G protein activation by agonists in intact versus destabilized oligomers may directly reflect the occupancy of binding sites. We have previously shown in mGlu receptors, that two agonists are more efficient in G protein activation compared to a single ligand-bound dimer . In addition, we had previously set up conditions that allowed insertion of a GABA binding deficient heterodimers in the oligomers (Comps-Agrar et al., 2011) . This similarly resulted in an increase in G protein-coupling efficacy. Altogether, these observations support the existence of a negative control between GABA B1 binding domains within the GABA B receptor oligomers for both agonist and antagonist binding. Such finding provide a rational explanation for the proposed hypothesis that only one heterodimer is functional in a tetrameric element of the GABA B oligomer.
What would be the physiological significance of having GABA B receptor oligomers activating a limited number of G proteins compared to heterodimers activating a G protein with maximum efficiency (Fig. 5) ? We could speculate that, in vivo, an equilibrium exists between oligomers and heterodimers such that oligomers constitute a storage pool of receptors that could be dissociated to increase the strength of the GABA B receptor response under some physiological contexts. Indeed, GABA B receptor is modulating the synaptic transmission throughout the brain and such a mechanism may prove to be important to protect the brain under certain physiological or pathophysiological circumstances. Additionally, the GABA B receptor oligomers could have some additional and still unknown signaling signatures by modulation other intracellular pathways that are not modulated by the heterodimers. Oligomers may also constitute signaling platforms with interacting proteins bound to the 'inactive' heterodimers placing them in spatial proximity to the 'active' heterodimers to modulate the signaling cascades. All these hypotheses are still very speculative but there are nonetheless compelling avenues which to address in a physiological context to decipher the role of the GABA B receptor oligomers in vivo. 
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